[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adaptive-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adaptive-treatment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100587624","liquid-biopsy-based-novel-modality-for-postoperative-management-of-lung-cancer-100587624",false,"NCT06930807","Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer","Development and Validation of Non-Invasive Monitoring Techniques for Postoperative Recurrence and Novel Adjuvant Therapeutic Strategies in Lung Cancer","Inclusion Criteria:\n\n* Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy\n* Solid nodules \\>1 cm or ground-glass nodules \\>1.5 cm on imaging\n* No history of malignancies other than non-small cell lung cancer in the past 5 years\n* Specimens are well preserved and imaging documents are accessible.\n\nExclusion Criteria:\n\n* Age\\\u003C18 years old\n* Non-small cell lung cancer with pathologic stage IIIB-IV (8th edition TNM classification)\n* Pathology results confirmed not to be non-small cell lung cancer\n* History of malignancies other than non-small cell lung cancer in the past 5 years","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer. The main questions this study aims to answer are:\n\n* How to develop multi-omics-based high-sensitivity detection methods to accurately capture MRD and monitor postoperative recurrence in lung cancer?\n* Is adaptive treatment guided by ctDNA-MRD for lung cancer patients superior to traditional clinical management and effectively improves survival?\n* Do heterogeneous patient populations (grouped by stages, histopathological subtypes, driver mutations, and treatment histories) show differences in effects under ctDNA-MRD guided postoperative management strategies?",[26,27,28],"Non-small Cell Lung Cancer","Minimal Residual Disease","Adaptive Treatment","RECRUITING","2025-04-08",{"date":32,"type":33},"2025-04-16","ACTUAL",{"date":35,"type":33},"2025-03-25",{"date":37,"type":20},"2028-07-31",{"name":39,"class":40},"Peking University People's Hospital","OTHER"]